Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Semaglutide 5mg

$90.00

Semaglutide is a synthetic peptide that functions as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a modified version of the naturally occurring GLP-1 hormone, with a molecular structure designed to make it more resistant to enzymatic breakdown in the body. This modification allows it to have a much longer half-life, enabling once-weekly administration rather than the several times a day injections required by older GLP-1 analogues. By mimicking the actions of the native GLP-1 hormone, Semaglutide performs several key physiological functions. It stimulates insulin secretion from the pancreas in a glucose-dependent manner, meaning it only works when blood sugar levels are high, thereby reducing the risk of hypoglycemia. It also suppresses the release of glucagon, a hormone that raises blood sugar. Furthermore, it slows down gastric emptying, which helps to increase feelings of fullness (satiety) and reduce appetite. This multi-pronged action makes it highly effective for both blood sugar control and weight management.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉
CAS Number 910463-68-2
Molar Mass 4,113.64 g/mol
Amino Acid Sequence H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
PubChem CID 56843331
Primary Research Area GLP-1 Receptor Agonist
Type 2 Diabetes Mellitus (T2DM) Treatment
Chronic Weight Management (Overweight/Obesity)
Reduction of Major Adverse Cardiovascular Events
Slow Gastric Emptying
Increase Pancreatic β-cell Proliferation
Reduce Glucagon Release
Influence Hypothalamic Pathways (Appetite/Satiety)
Purity >99%
Research Summary Description
Once-weekly semaglutide in adults with overweight or obesity Summary: The STEP 1 trial showed a mean weight loss of 14.9% with once-weekly subcutaneous semaglutide 2.4 mg in individuals with overweight or obesity without type 2 diabetes.

Citation: Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I.,... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial Summary: The STEP 8 trial directly compared subcutaneous semaglutide (Wegovy®) to subcutaneous liraglutide for weight loss. Semaglutide proved superior, achieving a mean weight loss of -15.8% compared to -6.4% with liraglutide.

Citation: Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rowe, E., Bartley, D.,... & STEP 8 Investigators. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150.
Oral Semaglutide and cardiovascular outcomes in high-risk Summary: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events.

Citation: Husain, M., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A.,... & PIONEER 6 Investigators. (2019). Oral Semaglutide and Cardiovascular Outcomes in High-Risk. New England Journal of Medicine, 381(9), 842-851.
Semaglutide for the treatment of overweight and obesity: A review Summary: This review highlights that among patients who persisted with semaglutide for obesity, the average reduction in body weight was -12.9% at one year, compared to -5.9% with semaglutide for type 2 diabetes.

Citation: Gasoyan, H., Kim, J., & Kim, Y. (2024). Semaglutide for the treatment of overweight and obesity: A review. Obesity Reviews, 25(10), e13788.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Summary: In individuals with both overweight/obesity and type 2 diabetes, the STEP 2 trial reported a mean weight loss of -9.6% with semaglutide 2.4 mg and a mean HbA1c reduction of 1.6%.

Citation: Davies, M., Færch, L., Jeppesen, O. K., Pakarinen, M., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes Summary: The SUSTAIN 6 trial investigated semaglutide's cardiovascular benefits in patients with T2DM. It demonstrated a reduction in a composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Citation: Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, J. A.,... & SUSTAIN 6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

Once-weekly semaglutide in adults with overweight or obesity

Summary: The STEP 1 trial showed a mean weight loss of 14.9% with once-weekly subcutaneous semaglutide 2.4 mg in individuals with overweight or obesity without type 2 diabetes.

Citation: Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I.,... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial

Summary: The STEP 8 trial directly compared subcutaneous semaglutide (Wegovy®) to subcutaneous liraglutide for weight loss. Semaglutide proved superior, achieving a mean weight loss of -15.8% compared to -6.4% with liraglutide.

Citation: Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rowe, E., Bartley, D.,... & STEP 8 Investigators. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150.

Oral Semaglutide and cardiovascular outcomes in high-risk

Summary: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events.

Citation: Husain, M., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A.,... & PIONEER 6 Investigators. (2019). Oral Semaglutide and Cardiovascular Outcomes in High-Risk. New England Journal of Medicine, 381(9), 842-851.

Semaglutide for the treatment of overweight and obesity: A review

Summary: This review highlights that among patients who persisted with semaglutide for obesity, the average reduction in body weight was -12.9% at one year, compared to -5.9% with semaglutide for type 2 diabetes.

Citation: Gasoyan, H., Kim, J., & Kim, Y. (2024). Semaglutide for the treatment of overweight and obesity: A review. Obesity Reviews, 25(10), e13788.

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Summary: In individuals with both overweight/obesity and type 2 diabetes, the STEP 2 trial reported a mean weight loss of -9.6% with semaglutide 2.4 mg and a mean HbA1c reduction of 1.6%.

Citation: Davies, M., Færch, L., Jeppesen, O. K., Pakarinen, M., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Summary: The SUSTAIN 6 trial investigated semaglutide's cardiovascular benefits in patients with T2DM. It demonstrated a reduction in a composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Citation: Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, J. A.,... & SUSTAIN 6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping